Viking Therapeutics (VKTX) Corporate presentation summary

Strategic focus and pipeline

• Focused on developing novel therapeutics for metabolic and endocrine diseases, with multiple clinical programs showing strong efficacy data.

• Lead asset VK2735, a dual GLP-1/GIP agonist, is being developed in both subcutaneous and oral formulations for obesity, with Phase 3 and Phase 2 studies underway or completed.

• Additional pipeline includes VK2809 for MASH (Phase 2b completed) and VK0214 for X-ALD (Phase 1b completed), plus an amylin agonist IND planned for 1Q26.

VK2735 clinical results and efficacy

• VK2735 demonstrated up to 14.7% mean weight loss after 13 weeks in subcutaneous Phase 2 studies, with dose-dependent, progressive effects and no plateau.

• Oral VK2735 achieved up to 12.2% mean weight loss after 13 weeks in Phase 2, with most weight loss maintained for weeks after dosing ended.

• Both formulations showed rapid, significant weight loss compared to placebo, with efficacy retained post-treatment.

Safety and tolerability

• Across studies, 92–99% of adverse events were mild to moderate, with GI-related events (nausea, vomiting, diarrhea, constipation) most common and generally transient.

• GI side effects were dose-dependent and occurred mainly early in treatment, subsiding over time; titration rate impacted tolerability.

• Discontinuation rates increased with higher doses but were generally low at potential future dose ranges.